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Purpose: The objective of the study was to develop matrix tablets for oral controlled release of 
aceclofenac using ethyl cellulose, guar gum and various grades of cellulose polymers.  
Methods: Possible drug-excipient interaction was evaluated by high performance liquid chromatography 
(HPLC) and Fourier infrared spectroscopy (FTIR). The tablets prepared were assessed for their 
physicochemical, in vitro drug release at pH1.2, 4.5, 6.8 and 7.5 and stability characteristics. 
Comparison with a ‘once daily’ commercial aceclofenac product was made in the in vitro studies. 
Results: There was no interaction between aceclofenac and the polymers used as excipients.  
Furthermore, the physicochemical properties of the tablets were satisfactory. The release profile of one 
of the formulated aceclofenac tablets (F7), which contained hydroxypropyl methyl cellulose (HPMC 
K4M), was statistically similar (p < 0.05) to that of the commercial aceclofenac brand in all the 
dissolution media. The formulated products ware stable and showed no changes in physical 
appearance, drug content, or dissolution pattern after storage at 40 
o
C /75 %RH for 6 months.  
Conclusion: The results indicate that it is feasible to achieve a stable ‘once daily’ sustained release 
aceclofenac tablet formulation by using HPMC K4M of 4000cps viscosity grade as matrix material. 
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INTRODUCTION 
 
Aceclofenac is a newer derivative of the 
diclofenac group of non-steroidal anti- 
inflammatory drug (NSAID) that exhibits 
analgesic and anti-inflammatory activities. It 
directly blocks the prostaglandin synthesis 
and has less gastrointestinal complications 
[1-3]. It is a recommended first-line drugs in 
the symptomatic treatment of rheumatoid 
arthritis, Osteoarthritis and ankylosing 
spondylitis. Aceclofenac, i.e., 2-{2-{2-(2,6-
dichlorophenyl)amino}phenyl}acetyl]oxy]ace- 
tic acid, has  a  short biological half life of 
approx 4 h and  a dosing frequency of 200 
mg daily in two  divided doses [4-6]. 
Consequently, the drug is a good candidate 
for sustained release formulation. 
 
Several matrix based sustained release 
products of aceclofenac utilizing hydrophilic 
and hydrophobic polymers have been 
reported [7-13]. Polymer matrix systems have 
the advantages of prolonging drug release 
and reducing adverse effects in patients. An 
attempt has been made in the present study 
to achieve suitable aceclofenac therapeutic 
profile by formulating sustained release 
tablets using various viscosity grades of 






Aceclofenac was a gift from Mepro 
Pharmaceuticals Pvt. Ltd. Surendranagar, 
India  while Aroff SR tablets (Unichem Lab, 
Mumbai, India), used as a reference, were 
purchased from a local pharmacy. The 
excipients used in the production of the 
tablets were Methocel K4M, K15M and 
K100M Premium (Colorcon Asia Pvt Ltd, 
Singapore), which represent hydroxypropyl 
methylcellulose (HPMC) viscosity grades 
4000, 15000 and100000 cps, respectively; 
guar gum (Kachabo Gum, India); ethyl 
cellulose 20 cps (Feicheng  Ruotai Fine 
Chemicals Co., Ltd, China);  Methocel E 15  
(Colorcon Asia Pvt. Ltd., Singapore),which 
represents HPMC viscosity grade 15 cps  
and lactose (DMV International, USA). Others 
were polyvinyl pyrollidone (PVP) K-30, 
(International Fine Chemicals Inc,, Canada), 
sodium propyl paraben (Salicylates and 
Chem Pvt Ltd, India), fumaric acid, 
microcrystalline cellulose (MCC, Avicel 
PH102, FMC Biopolymers, U.S.A.), 
magnesium stearate (Nitika Chemicals, 
India), talc (Udaipur Mineral Development 
Syndicate Pvt Ltd, India), isopropyl alcohol 
(Ranbaxy Fine Chemicals, India), methylene 
chloride (Chemplast Sanmar Ltd, India) 
titanium dioxide (Dupont Company Pvt Ltd, 
Singapore), PEG-6000 (Manali Petro 
Chemicals, India), castor oil (Sundarballi Oil 
Mill, India) and Ponceau 4 R supra (Roha 
Dye Chem, India). All other chemicals used 
were of analytical grade. 
 
Solubility studies on aceclofenac 
 
Loose bulk density (LBD) and tapped bulk 
density (TBD) were determined with a density 
apparatus (Serwell, Bangalore, India) while 
Carr's index and the Hausner's ratio were 
calculated using Eqs 1 and 2. 
 
Carr’s index (%) = TBD - LBD/TBD × 100… .(1)   
 
Hausner’s ratio = TBD/LBD …………………..(2) 
 
Evaluation of drug-excipient compatibility 
 
Different excipients were selected and mixed 
separately with aceclofenac in proportions 
generally used in tablet formulations. Sets 
(23 each) of mixture were prepared, and 
stored in a closed chamber for 2 weeks at 
40º C/75% RH closed. The physiochemical 
compatibilities of the drug and the excipients 
were evaluated by high performance liquis 
chromatography (HPLC, Class VP series, 
Shimadzu Corporation, Kyoto, Japan). 
 
Infrared (IR) spectroscopy was conducted 
using a Perkin Elmer FTIR Spectrum-100 
spectrophotometer and the spectra were 
recorded in the wavelength region of 4000 to 
450 cm
−1
. The procedure consisted of 
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dispersing the sample (drug alone or mixture 
of drug and excipient) in KBr and then 
compressing into discs by applying a 
pressure of 5 tons for 5 min in a hydraulic 
press. The pellet was placed in the light path 
and the spectrum obtained.  The energy at 
which any peak in an absorption spectrum 
appears corresponds to the frequency of a 
vibration of a part of a sample molecule [14].  
 
Assay of aceclofenac 
 
Quantitative determination of aceclofenac 
was performed by HPLC. A gradient HPLC 
(Shimadzu Corporation, Kyoto, Japan) with 
2LC -10AT VP pumps, a variable wavelength 
programmable UV/VIS Detector SPD-10A 
VP, aCTO-10AS VP column oven and Inertsil 
ODS, C18, 250 x 4.6 mm, 5µ column was 
used. The HPLC system was equipped with 
the software Class –VP series version 5.03. 
The mobile phase used was a mixture of 
buffer and acetonitrile in a ratio of 3:2 (The 
buffer was prepared by mixing1.2 ml of 
glacial acetate with water and making it up to 
1000 ml with more water while adjusting the 
pH to 5.2 with triethyl amine). The filtered 
mobile phase was pumped at a flow rate of 
1.5 ml/min and the column temperature was 
maintained at 30 
0
C.The eluent was detected 
by a UV detector at 281 nm.  
 
Preparation of matrix tablets  
 
The tablets were prepared by a wet 
granulation technique. The composition of the 
tablet formulations are given in Table 1. 
Aceclofenac, HPMC, guar gum, ethyl 
cellulose, lactose/maize starch, sodium 
propyl parabenzoate and fumaric acid were 
screened through a 425 µm  sieve and mixed 
manually in a bowl for 5 min. The blend was 
granulated with the aid of PVP K-30 and 
water. The mass was sieved through a 500 
µm sieve and then dried in a hot air oven at 
50 
0
C. Magnesium stearate, talc and colloidal 
silicon dioxide were then added to the dried 
granules, mixed for about 5 min in a 
polythene bag and compressed into tablets 
using a 12- station tablet compression 
machine (CIP Machineries, Ahmadabad, 
India) equipped with a 11mm biconcave-
faced punches. To mask the bitterness of the 
aceclofenac API , a selected batch (F7) was 
coated in a laboratory coater (Model GAC-
250, Gansons Ltd, Mumbai, India) with  
HPMC 5 cps as coating polymer dissolved in 
isopropyl alcohol and methylene chloride; 
titanium dioxide  and ponceau 4 R supra as 
colouring agents, PEG-6000 (polyethylene 
glycol-6000) and castor oil were used as 
plasticizers. 
 
Physiochemical characterization of the 
tablets  
 
Tablet weight variation was evaluated using 
10 tablets with an electronic balance (Mettler 
Toledo, Mettler, Griefensee, Switzerland) 
while tablet hardness and friability were 
determined for 10 tablets using a Monsanto 
(standard type) tablet hardness tester and a 
Campbell electronic friabilator for 4 min at 25 
rpm, respectively. 
 
Evaluation of in-vitro release  
 
In vitro dissolution test was carried out using 
USP Type 2 dissolution apparatus in 900 ml 
of simulated pH1.2 for the  first 2 h and then 
in  phosphate buffer (pH 7.5) from 3 to 12 h. 
The dissolution medium was kept in 
thermostatically controlled water bath, 
maintained at 37 ± 0.5
o
C. The pre-weighed 
tablet was then introduced into the dissolution 
jar and the paddle was rotated at 100 rpm. At 
different time intervals, a 5ml sample was 
withdrawn and analyzed spectrophoto-
metrically at 275 nm for the drug release. At 
each time of withdrawal, 5 ml of the fresh 
corresponding medium was added to the 
dissolution flask. The studies were also 
carried out were also repeated but 
substituting acetate buffer (pH 4.5) or 
phosphate buffer (pH 6.8) for phosphate 
buffer (pH 6.8). The dissolution data obtained 
were fitted to zero order, first order, Higuchi, 
Hixson-Crowell and Korsmeyer- Peppas 
models to determine the rate and mechanism  
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Table 1: Composition of sustained release tablet formulations  
 
    Ingredient 
      
F1 F2 F3 F4 F5 
(mg/tablet) 
F6 F7 F8 F9 F10 
Methocel K4M 20 -- --- --- --- -- 37.5 --- --- --- 
Methocel K15M  --- 20 --- --- --- --- --- 15 --- --- 
Methocel K100M --- --- 15 --- --- --- --- --- 10 --- 
Guar gum --- --- --- 15 --- --- --- --- --- --- 
Ethyl cellulose (20cps) ---- --- --- --- 20 --- --- --- --- 40 
Methocel E15 ---- --- --- --- --- 50 --- --- ---- -- 
Avicel PH102 9.5 9.5 9.5 9.5 9.5 -- -- --- --- -- 
Colloidal silicon  
dioxide (Aerosil) 
4 4 4 4 4 4 4 4 4 ------ 
Maize starch 33 33 38 38 33 12.5 33 47.5 52.5 28 
Lactose 30 30 30 30 30 30 30 30 30 28.5 
Purified water Q.S Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. 
Each formulation also contains 200mg aceclofenac; 7.5 mg PVP K-30;, 2 mg sodium propyl paraben; 10 
mg fumaric acid; 4mg magnesium stearate; and 5 mg talc. Compressing weight of each formulation was 
325 mg. 
 
of aceclofenac release using eqs. 5,6,7,8 and 
9, respectively.  
 
Q = kot   ………………………... (3) 
 
where Q is the amount of drug release at 
time t and ko is the zero order release    
 constant and t is time 
 
In (100 – Q) = In Qo-k ....................... (4) 
 
where Q is the amount of drug release at 




   …………….………….. (5) 
where Q is the amount of drug release at 
time t and kh is the Higuchi square root of 




   - W
1/3
 =  K
1/D
 ……….........……… (6) 
 
where Wo is the initial weight ,W is the weight 
remaining and K
1/D
 is the cube root  
dissolution expression. 
 
Qt /Q = kt
n
 ……………….………..…….. (7) 
  
where Qt /Q is the fraction of drug released at 
time t, k is a constant comprising the 
structural and geometric characteristics of the 
tablet and n is the release exponent. 
Difference factor (f1) and similarity factor (f2) 
were also calculated using Eqs 8 and 9 to 




| Rt – Tt |) (Σ = 1
n 
Rt)}. 100 ..…………. (8) 
 
f2= 50. Log {(1+ (1/n) Σ=1
n




. 100}….  (9) 
 
where n = no. of full points, Rt = the reference 
profile at the time point, t, and Tt = the test 
profile at the same point. 
 
Stability studies  
 
Stability studies were conducted on a strip 
pack of one of the aceclofenac test 
formulation (F7) in order to assess its stability 
after storage at 40 
o
C/75 %RH for 6 months. 
Samples were withdrawn at 1, 3 and 6 
months and evaluated for appearance, 
friability, hardness, drug content and in vitro 
drug release. 
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Data analysis 
 
Student’s t-test was employed to analyze the 
results using Graph Pad Instat Software, 
version 1.13.  Differences below the 









Figure 2: FTIR spectrum of aceclofenac tablets 




Solubility of aceclofenac 
 
The solubility of aceclofenac (mg/ml) was as 
follows: water, 0.077 ± 0.010; 0.1M HCl 
(pH1.2), 0.012 ± 0.010; pH 4.5 acetate buffer, 
0. 184 ± 0.010; pH 6.8 phosphate buffer, 
0.784 ± 0.010 and pH 7.5 phosphate buffer, 




Aceclofenac powder exhibited an angle of 
repose of 52.03 ± 0.034
o
, Carr’s index of  




The pure aceclofenac powder, when kept for 
2 weeks at 60
0 
C in a well-closed container, 
turned lumpy and off-white from the initial 
white crystalline powder. On the other hand, 
no change in appearance and level of 
impurity (determined by HPLC) was noticed 
when it was stored at 40
0 
C/75% RH for 2 
weeks. 
 
Figs 1 and 2 show the spectra of the pure 
drug and tablet formulation (F7), respectively. 
The spectrum for pure aceclofenac showed 
major peaks at the following wave numbers:  
3319.39,1771.71,17I7.12,1589.69,1508.14,1
452.50,1418.56,1344.80,1256.64,1150.53, 
1056.35, 899.33, 749.96, 668.15 and 625.98 
cm
-1
. Formulation F7 spectrum also showed 
similar peaks at the above wave numbers. 
 
The difference factor (f1) and similarity factor 
(f2),when the drug release data for F7 and   
the reference product were compared in 
various dissolution media were as follows: 
pH1.2, f1 = 4.04, f2 = 99.29; pH 4.5, f1 = 
3.04, f2 = 94.94; pH 6.8, f1 = 3.68, f2 = 
82.06; and pH 7.5, f1 = 2.44, f2 = 82.89. Drug 
release from F7 in the various pH media was 
similar to that of the reference tablet thus 
indicating that both formulations behaved in a 
similar manner in all the tested dissolution 
media. For the test product to be identical 
with reference product for drug release 
pattern, low f1 values (usually < 15) and high 
f2 values (> 50) are desirable.   
 
Physicochemical properties of the 
formulated tablets  
 
Tablet thickness was in the range 3.6 -3.9 
mm; diameter, 11.0mm; and hardness, 5.0 -
8.0 kg/cm
2
. Tablet friability and coefficient of  
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Table 2 In vitro release profile of the prepared aceclofenac sustained release tablets in pH 1.2 and pH7.5 
media 
 
Drug release (%) Formulation 
      2 h       4 h       6 h      8 h   12 h 
F1 2.0±0.2 ns 49±0.20 s 70±0.12 s 88±0.12 s 96±0.15 ns 
F2 1.8±0.3 ns 27±0.17 s 30±0.17 s 42±0.11 s 52±0.09 s 
F3 0.7±0.2 s 18±0.15 s 26±0.21 s 38±0.13 s 42±0.04 s 
F4 1.5±0.3 ns 22±0.12 s 32±0.22 s 47±0.12 s 58±0.06 s 
F5 2.2±0.1 ns 42±0.11 s 72±0.14 s 86±0.11 s 97±0.01 ns 
F6 2.8±0.2ns 76±0.17s 88±0.11s 99±0.13s 103±0.01s 
F7 2.4±0.2ns 40±0.09s 59±0.12ns 70±0.12s 92±0.06s 
F8 2.0±0.2ns 34±0.11s 50±0.12s 60±0.15s 66±0.04s 
F9 2.5±0.3ns 26±0.12s 32±0.13s 46±0.14s 59±0.08s 
F10 2.1±0.2ns 32±0.15s 69±0.12s 89±0.15s 95±0.09ns 
Reference 2.2±0.3 39±0.11 59±0.11s 68±0.14 96±0.14 
*All values are expressed as mean ± SD (n=20); s = significantly different; and ns = not significantly 
different, when compared to reference product (p > 0.05)  
 
Table 3: Comparative in vitro release profile of a test aceclofenac sustained release formulation 
(F7) and reference product at pH1.2, 4.5 and 6.8  
 
                                Drug release (%) Product Dissolution 






























Note: Results are mean ± S.E.M. (n = 3); s = significantly different; ns = not -significantly 
different (p > 0.05), compared to the reference product. 
 
weight variation of all the tablet batches were 
in the ranges 0.5 to 0.8 % and 1.4 to 3.5 %, 
respectively. Drug content was satisfactory 
and uniform (> 99 %) for all the batches of 
tablet formulations. 
 
In vitro drug release 
 
The results of the in vitro drug release studies 
in simulated gastric and intestinal fluids are 
presented in Table 2. It is evident that,  after 
2 h in pH1.2 and from 3 to 12 h in  pH 7.5 
buffer,  formulations F1, F5 and F6 followed 
Hixson-Crowell cube root release pattern, 
while formulations F2, F3, F4, F8 and F9 
followed Korsmeyer-Peppas release pattern; 
formulation F7, Higuchi release pattern; and 
formulation F10, first order release pattern. 
 
As shown in Table 3, drug release data for 
the reference tablets and test formulation F7 
in different pH media were similar, indicating 
both exhibited similar characteristics.  
 
Accelerated stability studies 
 
The results obtained from accelerated 
stability studies indicate that F7 tablets 
(which were packed in aluminium strips) did 
not show any physical changes (appearance, 
friability and hardness) after 6 months. Drug 
content (mean ± SD, n=3) was 100.4 ± 0.22 
% at 0 month; 100 ± 0.44 % at month 1 ; 99.8 
± 0.51 % at month 3; and 98.6 ± 0.20  %  at  
month 6 . These data were not significantly 
different (p < 0.05).  Furthermore, there was 
also no significant change (p > 0.05) in the 
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The available literature on the solubility 
profile of aceclofenac indicates that the drug 
is freely soluble in acetone and practically 
insoluble in water [3].  In the present study, 
aceclofenac showed pH-dependent solubility;  
as pH was raised from 1.2 to 7.5, solubility 
improved considerably.  
 
Micromeritic properties  
 
Aceclofenac powder has very
 
poor flow 
properties as shown by high values of Carr’s 
index and Hausner’s ratio. However, 
aceclofenac granules exhibited considerably 
better flow properties with angle of repose, 
Carr’s index and Hausner’s ratio of 30
0
, 18.5 
% and 1.22, respectively. 
 
Compatibility and tablet properties 
 
There was no interaction between 
aceclofenac and the excipients used, thus 
indicating that the choice of excipients for the 
matrix tablets was suitable. Furthermore, all 
the formulations showed satisfactory 
hardness, friability and drug content. 
 
In vitro drug release  
 
All the matrix formulations, except F6, did not 
disintegrate within the 2-hour dissolution test 
period in pH 1.2 buffer. The disintegration of 
F6 tablets is probably due to the fact its 
matrix consisted of low – viscosity HPMC 
which is more soluble than the higher 
viscosity grades of the polymer. F1, F7 and 
the reference tablets, though swollen, 
retained their shape throughout the 12-hour 
dissolution test period. However, all the 
formulations, including the reference, showed 
biphasic release profile with slow drug 
release from 0 to 2 h followed by faster by but 





Such biphasic release pattern may be 
beneficial in providing therapeutically 
effective extended plasma concentration. The 
drug present on the surface of the matrix 
tablet did not produce a ‘burst’ release due 
probably to the low solubility of the drug at pH 
1.2. 
 
Over the dissolution period of 12 h, release 
rate decreased as the concentration of 
HPMC increased. HPMC matrix generates an 
additional osmotic gradient, thereby resulting 
in a faster rate of polymer swelling and a 
large increase in gel thickness. At higher 
polymer loading, the viscosity of the gel 
matrix increases which resulted in a decrease 
in the effective diffusion coefficient of the 
drug [16]. Wan et al have also reported that 
other factors that may contribute to 
differences in drug dissolution profile as a 
function of changes in total polymer 
concentration include differences in water 
penetration rate, water absorption capacity 
and polymer swelling [17]. Incorporation of 
either ethyl cellulose (F4 and F10) or guar 
gum (F4) also resulted in controlled drug 
release. This may be attributed to decreased 
penetration of the dissolution fluid in the 
presence of the hydrophobic polymers, 
leading to reduced diffusion of the drug from 
the matrix. 
 
In order to more closely compare the release 
properties of formulation F7 and the 
reference product, further dissolution studies 
were carried out at pH 1.2 for 2 h and then 
sequentially in acetate buffer (pH 4.5) and 
phosphate buffer (pH 6.8) from 3 to 12h. The 
results indicated close similarity between the 
two products based on the low f1 (< 15) and 
high f2 values (> 50). Thus it can be said that 
the F7 tablets (containing 18.75 %w/w HPMC 
K4M) was similar to the commercial brand of 
aceclofenac (reference) with regard to drug 
release. 
 
On subjecting the release data to Hixson-
Crowell cube root models, F1, F5 and F6 
showed linearity with regression coefficients 
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of between 0.9711 and 0.9915. The model 
characterizes drug release from a matrix 
tablet containing hydrophilic polymers and 
generally involves factors of diffusion.  Drug 
release from swollen matrices is dependent 
on the diffusion and relaxation behavior of the 
dosage form. Diffusional release occurs by 
molecular diffusion and relaxation behavior of 
the dosage form. Diffusional release occurs 
by molecular movement down a chemical 
potential gradient while relaxational release is 
by a drug transport mechanism that is 
associated with stresses and state transitions 
involved in the swelling of the hydrophilic 
polymer. Thus, the swelling of the polymer 
would be expected to alter drug concentration 
gradient in the gel layer and hence diffusion 
path length and drug release [18]. This 
explains why a drug diffuses at a 
comparatively slower rate as the diffusion 
path length increases; this is governed by the 
square – root or Higuchi model. F7 showed 
high linearity (r
2
 = 0.9948)  and thus fitted 
well to the Higuchi model. Further elucidation 
of the release mechanisms involved indicate 
that F2, F3, F4, F8 and F9 fitted into the 
Korsmeyer-Peppas model, with r
2 
values of 
0.9718 to 0.9918. This indicates a coupling of 
diffusion and erosion mechanisms - the so-
called anomalous diffusion. On the other 
hand, F10 fitted best to first order release 
kinetics with r
2




We found that the incorporation of HPMC 
K4M (4000 cps) in matrix tablets of 
aceclofenac not only aided initial retardation 
in drug release but also enhanced the 
attainment of controlled drug release after a 
suitable lag time. The formulation method 
employed is simple and should be adaptable 
for commercial scale up. 
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